| ·美批准Perjeta(pertuzumab)乳腺癌三联疗法 | 2018-01-10 17:50:07 |
| ·Pertuzumab+曲妥珠单抗乳腺癌3期试验获肯定结果 | 2017-03-29 17:31:51 |
| ·CHMP推荐Perjeta用于HER2阳性早期乳腺癌 | 2015-07-01 14:40:38 |
| ·Perjeta(pertuzumab)延长乳腺癌患者长生存期 | 2014-09-29 15:02:38 |
| ·抗肿瘤药物帕妥珠单抗 (Pertuzumab)介绍 | 2014-09-02 16:48:40 |
| ·Perjeta寻求用于早期HER2阳性乳腺癌 | 2013-07-05 09:46:51 |
| ·欧洲批准Perjeta(Pertuzumab)用于乳腺癌 | 2013-03-06 14:22:08 |
| ·CHMP支持批准Perjeta用于乳腺癌 | 2012-12-19 10:27:35 |
| ·试验显示Perjeta延长乳腺癌患者生存时间 | 2012-12-11 11:42:51 |
| ·美批准Perjeta(Pertuzumab)用于晚期乳腺癌 | 2012-06-11 10:14:34 |
| ·Pertuzumab申请用于HER2阳性晚期乳腺癌 | 2012-02-10 09:28:58 |
| ·基因泰克转移性乳腺癌3期试验达终点 | 2011-07-18 10:48:53 |
| ·Pertuzumab乳腺癌一项3期试验获肯定结果 | 2011-07-18 09:56:47 |